CN107406447A - 吡咯并吡啶化合物的结晶形式 - Google Patents

吡咯并吡啶化合物的结晶形式 Download PDF

Info

Publication number
CN107406447A
CN107406447A CN201680011960.5A CN201680011960A CN107406447A CN 107406447 A CN107406447 A CN 107406447A CN 201680011960 A CN201680011960 A CN 201680011960A CN 107406447 A CN107406447 A CN 107406447A
Authority
CN
China
Prior art keywords
bromo
pyrrolo
pyridin
aminopiperidin
bases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680011960.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·斯塔尔茨
C·M·林德曼
K·L·斯宾塞
W·刘
J·卢巴赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107406447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CN107406447A publication Critical patent/CN107406447A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680011960.5A 2015-02-26 2016-02-26 吡咯并吡啶化合物的结晶形式 Pending CN107406447A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
US62/121,396 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (1)

Publication Number Publication Date
CN107406447A true CN107406447A (zh) 2017-11-28

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680011960.5A Pending CN107406447A (zh) 2015-02-26 2016-02-26 吡咯并吡啶化合物的结晶形式

Country Status (21)

Country Link
US (2) US20160251350A1 (https=)
EP (1) EP3262042A1 (https=)
JP (1) JP2018506562A (https=)
KR (1) KR20170118762A (https=)
CN (1) CN107406447A (https=)
AR (1) AR103801A1 (https=)
AU (1) AU2016225070A1 (https=)
BR (1) BR112017018230A2 (https=)
CA (1) CA2976665A1 (https=)
CL (1) CL2017002180A1 (https=)
CO (1) CO2017009662A2 (https=)
CR (1) CR20170439A (https=)
HK (1) HK1246786A1 (https=)
IL (1) IL254115A0 (https=)
MA (1) MA41599A (https=)
MX (1) MX2017010888A (https=)
PE (1) PE20171327A1 (https=)
PH (1) PH12017501532A1 (https=)
RU (1) RU2017133093A (https=)
SG (1) SG11201706824TA (https=)
WO (1) WO2016138458A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385871A (zh) * 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260868A1 (en) * 2009-04-11 2010-10-14 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CN102089307A (zh) * 2008-05-13 2011-06-08 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089307A (zh) * 2008-05-13 2011-06-08 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
US20100260868A1 (en) * 2009-04-11 2010-10-14 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors

Also Published As

Publication number Publication date
CL2017002180A1 (es) 2018-03-16
KR20170118762A (ko) 2017-10-25
HK1246786A1 (zh) 2018-09-14
PE20171327A1 (es) 2017-09-12
WO2016138458A1 (en) 2016-09-01
IL254115A0 (en) 2017-10-31
AR103801A1 (es) 2017-06-07
SG11201706824TA (en) 2017-09-28
PH12017501532A1 (en) 2018-02-05
MA41599A (fr) 2018-01-02
AU2016225070A1 (en) 2017-09-07
US20160251350A1 (en) 2016-09-01
US20180282324A1 (en) 2018-10-04
BR112017018230A2 (pt) 2018-04-17
JP2018506562A (ja) 2018-03-08
EP3262042A1 (en) 2018-01-03
CR20170439A (es) 2018-01-08
MX2017010888A (es) 2017-12-15
RU2017133093A (ru) 2019-03-26
CO2017009662A2 (es) 2018-02-28
RU2017133093A3 (https=) 2019-08-23
CA2976665A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
TWI752580B (zh) Kras突變蛋白抑制劑
US20240059669A1 (en) Cocrystal of a cdk inhibitor
CN109415340B (zh) N-{6-(2-羟基丙-2-基)-2-[2-(甲基磺酰基)乙基]-2h-吲唑-5-基}-6-(三氟甲基)吡啶-2-甲酰胺的多晶型物
CN120548318A (zh) Kras g12d抑制剂和其用途
CN107660202B (zh) 水溶性前药
CN112839646A (zh) 用于治疗医学疾病的苯并噻吩雌激素受体调节剂
CN110461853A (zh) 苯并噻吩雌激素受体调节剂
TW201134820A (en) Arylsulfonamide CCR3 antagonists
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2017202311A1 (zh) 一种2-氨基嘧啶类化合物的多晶型形式
WO2007123511A2 (en) Dosing regimens for the treatment of cancer
CN107406447A (zh) 吡咯并吡啶化合物的结晶形式
EA028059B1 (ru) Твердые формы n-((s)-2,3-дигидроксипропил)-3-(2-фтор-4-йодфениламино)изоникотинамида
CN108473492B (zh) 用于医学应用的一种1,2,4-三唑并[4,3-a]吡啶的衍生物的新型结晶盐形式
WO2017071636A1 (zh) 酞嗪酮衍生物、其制备方法及用途
US20250353847A1 (en) Crystalline forms of an akric3 dependent kars inhibitor
JP2021527119A (ja) 塩形態
JP5872558B2 (ja) ピラゾリルアミノキナゾリンの臭化水素酸塩
TW201136899A (en) Isotopically enriched arylsulfonamide CCR3 antagonists
WO2026021563A1 (zh) 一种选择性抑制剂的多晶型物及其制备方法
HK40099717A (zh) Cdk抑制剂的共晶体
HK40101132B (zh) 作为pd-l1相互作用的免疫调节剂的杂环化合物
HK40074209A (en) Shp2 phosphatase inhibitors and methods of making and using the same
HK1254731B (zh) 用於医学应用的一种1，2，4-三唑并[4，3-a]吡啶的衍生物的新型结晶盐形式
HK40060539B (zh) 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171128

WD01 Invention patent application deemed withdrawn after publication